AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2801591 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin without Fe
Number of subjects: 2
Study 357128 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 58
Study 357128 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine-L-dopa-carbidopa
Number of subjects: 58
Study 357128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31220105 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-PGA 1,500 mg for 4 weeks
Number of subjects: 195
Study 31220105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 28355688 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 183
Study 28355688 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 183
Study 25886286 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component school-based intervention including curriculum component, mandatory daily hand washing before lunch, extra cleaning of school toilets
Number of subjects: 8438
Study 25886286 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 8438
Study 23924918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute moderate-intensity endurance exercise before influenza vaccination
Number of subjects: 59
Study 23924918 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (control group)
Number of subjects: 59
Study 23924918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute moderate-intensity endurance exercise
Number of subjects: 59
Study 22525000 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 22525000 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 22525000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22525000 — intervention group
Group type: COMPARATOR
Intervention: Combined Behavioral Intervention
Number of subjects: 0
Study 19409344 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus
Number of subjects: 24
Study 19409344 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond
Number of subjects: 24
Study 17883522 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep modification (BSM)
Number of subjects: 43
Study 17883522 — intervention group
Group type: COMPARATOR
Intervention: Placebo behavioral instructions
Number of subjects: 43
Study 15181395 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair Climbing (SC)
Number of subjects: 32
Study 15181395 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES)
Number of subjects: 32
Study 15181395 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair Climbing + Electrostimulation (SC+ES)
Number of subjects: 32
Study 11834105 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration (‐4% body mass)
Number of subjects: 14
Study 11834105 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated condition
Number of subjects: 14
Study 9000189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiandrogens (NSAAs) plus luteinizing hormone-releasing hormone (LHRH) or orchiectomy
Number of subjects: 9
Study 9000189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiandrogens (NSAAs)
Number of subjects: 9
Study 9000189 — intervention group
Group type: COMPARATOR
Intervention: LHRH or orchiectomy alone
Number of subjects: 9
Study 8229530 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (5 ml/kg) of protein-free synthetic surfactant (Exosurf) for rescue therapy
Number of subjects: 89
Study 8229530 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (5 ml/kg) of protein-free synthetic surfactant (Exosurf) for prophylactic therapy
Number of subjects: 89
Study 8229530 — intervention group
Group type: COMPARATOR
Intervention: Control subjects for prophylactic therapy
Number of subjects: 89
Study 8229530 — intervention group
Group type: COMPARATOR
Intervention: Control subjects for rescue therapy
Number of subjects: 89
Study 3743614 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapamil 300 mg thrice daily
Number of subjects: 24
Study 3743614 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 29847387 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with nerve blocks (bupivacaine and dexamethasone)
Number of subjects: 0
Study 29847387 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with nerve blocks (mepivacaine and propofol sedation)
Number of subjects: 0
Study 29847387 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with nerve blocks
Number of subjects: 0
Study 29847387 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with nerve blocks
Number of subjects: 0
Study 29847387 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia and spinal anesthesia
Number of subjects: 0
Study 26521158 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy devices with varying stability properties
Number of subjects: 25
Study 26521158 — intervention group
Group type: COMPARATOR
Intervention: Flat rigid surface
Number of subjects: 25
Study 24862029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar gene coexpression modules (tan module)
Number of subjects: 101
Study 24862029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar gene coexpression modules (light yellow module)
Number of subjects: 101
Study 22481687 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication treatment plus proton pump inhibitors
Number of subjects: 0
Study 22481687 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors alone
Number of subjects: 0
Study 22481687 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (not infected with H. pylori)
Number of subjects: 0
Study 19830661 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous double U-stitch gastrostomy
Number of subjects: 62
Study 19830661 — intervention group
Group type: COMPARATOR
Intervention: Previously published VAG technique (Control)
Number of subjects: 62
Study 17637413 — intervention group
Group type: COMPARATOR
Intervention: 4-strand hamstring graft (4SHG)
Number of subjects: 76
Study 17637413 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-strand hamstring graft (8SHG)
Number of subjects: 76
Study 16132805 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of hormone replacement therapy (HRT)
Number of subjects: 20671
Study 16132805 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of hormone replacement therapy (HRT) in women aged 65+
Number of subjects: 20671
Study 16132805 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of hormone replacement therapy (HRT) in women with BMI<30
Number of subjects: 20671
Study 16132805 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of hormone replacement therapy (HRT) in women who regularly use aspirin or ibuprofen
Number of subjects: 20671
Study 12006715 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 87
Study 12006715 — intervention group
Group type: COMPARATOR
Intervention: Traditional Care
Number of subjects: 87
Study 10456820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Number of subjects: 58
Study 10456820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 58
Study 7551625 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured psychiatric intervention consisting of health education, stress management/behavioral training, coping techniques, and psychosocial group support
Number of subjects: 0
Study 7551625 — intervention group
Group type: EXPERIMENTAL
Intervention: Active behavioral and cognitive coping strategies
Number of subjects: 0
Study 2024846 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement (telephone discussions about OSA severity, benefits of nCPAP, and minimizing side effects) for new nCPAP users during the reinforcement period (3 months).
Number of subjects: 9
Study 2024846 — intervention group
Group type: COMPARATOR
Intervention: No reinforcement for new nCPAP users during the nonreinforced period (3 months).
Number of subjects: 9
Study 2024846 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable chronic nCPAP users (not a part of the randomized study).
Number of subjects: 9
Study 7049817 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 100 mg once daily
Number of subjects: 40
Study 7049817 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine, 10 mg 3 times daily
Number of subjects: 40
Study 31821350 — intervention group
Group type: EXPERIMENTAL
Intervention: brief group-delivered motivational interviewing (bMI)
Number of subjects: 89
Study 31821350 — intervention group
Group type: COMPARATOR
Intervention: brief group-delivered cognitive-behavioral therapy (bCBT)
Number of subjects: 89
Study 27597425 — intervention group
Group type: EXPERIMENTAL
Intervention: EPLBD alone
Number of subjects: 86
Study 27597425 — intervention group
Group type: EXPERIMENTAL
Intervention: EST with EPLBD
Number of subjects: 86
Study 25727277 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized 45-minute multifaceted preoperative education
Number of subjects: 129
Study 25727277 — intervention group
Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 129
Study 23820061 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (treatment)
Number of subjects: 39
Study 23820061 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard treatment)
Number of subjects: 39
Study 22807609 — intervention group
Group type: EXPERIMENTAL
Intervention: Third Eye colonoscopy (TEC)
Number of subjects: 345
Study 22807609 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 345
Study 19362552 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg/d for 8 weeks followed by 4 weeks of placebo
Number of subjects: 120
Study 19362552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17699390 — intervention group
Group type: EXPERIMENTAL
Intervention: AA (Nutrineal 1.1%) plus G (Physioneal 1.36 to 3.86%)
Number of subjects: 12
Study 17699390 — intervention group
Group type: COMPARATOR
Intervention: G only (control dialysate)
Number of subjects: 12
Study 15126525 — intervention group
Group type: EXPERIMENTAL
Intervention: AndroGel (T gel) 1% CIII, 5, 7.5, or 10 g per day for up to 42 months
Number of subjects: 163
Study 11483282 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg recombinant HB vaccine
Number of subjects: 230
Study 11483282 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg recombinant HB vaccine
Number of subjects: 230
Study 11483282 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg recombinant HB vaccine
Number of subjects: 230
Study 9494307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-point numeric rating scale (NRS) for pain and discomfort rankings from 16 common procedures; N = 100
Number of subjects: 135
Study 9494307 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-point numeric rating scale (NRS) for pain and discomfort rankings; N = 35
Number of subjects: 135
Study 9494307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-point NRS reliability assessment with 30 additional subjects
Number of subjects: 135
Study 8035392 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient arthroscopic evaluation
Number of subjects: 33
Study 8035392 — intervention group
Group type: COMPARATOR
Intervention: Plain radiographs
Number of subjects: 33
Study 8035392 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 33
Study 8035392 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Number of subjects: 33
Study 2590612 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily for 12 days
Number of subjects: 30
Study 2590612 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily for 12 days with ranitidine 150 mg 30 min before aspirin
Number of subjects: 30
Study 2590612 — intervention group
Group type: COMPARATOR
Intervention: Control values (no aspirin)
Number of subjects: 30
Study 4919119 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 62
Study 4919119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31171470 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive calf muscle stretching (ankle dorsiflexion applied 30 min/d, 5 days/wk) for 4 weeks
Number of subjects: 13
Study 31171470 — intervention group
Group type: COMPARATOR
Intervention: Control (no muscle stretching for 4 weeks)
Number of subjects: 13
Study 28165273 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone-based motivational counseling
Number of subjects: 347
Study 28165273 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone-based reduction counseling
Number of subjects: 347
Study 28165273 — intervention group
Group type: COMPARATOR
Intervention: Active counseling (motivational and reduction)
Number of subjects: 347
Study 24921209 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy
Number of subjects: 498
Study 24921209 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 498
Study 23821090 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with BNP testing (n=697)
Number of subjects: 1374
Study 23821090 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (control condition; n=677)
Number of subjects: 1374
Study 21401949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day) for 10 days in non-drinkers (Trial 1)
Number of subjects: 185
Study 21401949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day) for 10 days in moderate drinkers (Trial 2)
Number of subjects: 185
Study 21401949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day) for 5 days in chronic alcohol abusers (Trial 3)
Number of subjects: 185
Study 21401949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen overdose (acute ingestion)
Number of subjects: 185
Study 21401949 — intervention group
Group type: COMPARATOR
Intervention: Non-acetaminophen hepatotoxin exposure
Number of subjects: 185
Study 18671775 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Bifidobacterium Longum)
Number of subjects: 30
Study 18671775 — intervention group
Group type: COMPARATOR
Intervention: Milk beverage containing no bacteria (placebo)
Number of subjects: 30
Study 17436826 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-minocycline 1 mg/kg daily
Number of subjects: 1038
Study 17436826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1038
Study 12854893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) chemotherapy via lumbar puncture (LP) for prophylaxis
Number of subjects: 49
Study 12854893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) chemotherapy via lumbar puncture (LP) for treatment
Number of subjects: 49
Study 12854893 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic agents that cross the blood-brain barrier for prophylaxis
Number of subjects: 49
Study 12854893 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic agents that cross the blood-brain barrier for treatment
Number of subjects: 49
Study 12854893 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS surveillance and prophylaxis practices
Number of subjects: 49
Study 12854893 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate in a randomized controlled trial (RCT)
Number of subjects: 49
Study 10879804 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 173
Study 10879804 — intervention group
Group type: COMPARATOR
Intervention: Control (unsupplemented)
Number of subjects: 173
Study 8707731 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 0
Study 8707731 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 1585840 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Image Detection Device (BIDD) - BPI
Number of subjects: 0
Study 1585840 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Image Detection Device (BIDD) - SRI
Number of subjects: 0
Study 1585840 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of weight dissatisfaction
Number of subjects: 0
Study 1585840 — intervention group
Group type: COMPARATOR
Intervention: Control group (psychiatric)
Number of subjects: 0
Study 6086435 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarettes with high delta 9-THC concentration
Number of subjects: 0
Study 6086435 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana cigarette
Number of subjects: 0
Study 31581920 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute Step Test (3MStepT)
Number of subjects: 50
Study 31581920 — intervention group
Group type: COMPARATOR
Intervention: 6-minute Walk Test (6MWT)
Number of subjects: 50
Study 29741665 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility criteria predicting STI diagnoses
Number of subjects: 1774
Study 29741665 — intervention group
Group type: COMPARATOR
Intervention: Participants enrolled outside eligibility criteria
Number of subjects: 1774
Study 27597866 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 20
Study 27597866 — intervention group
Group type: COMPARATOR
Intervention: Conventional bur technique
Number of subjects: 20
Study 24886272 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily for 40 weeks
Number of subjects: 240
Study 24886272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive)
Number of subjects: 240
Study 22324460 — intervention group
Group type: EXPERIMENTAL
Intervention: NiTiR technique (after education)
Number of subjects: 850
Study 22324460 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel hand instrumentation (before education)
Number of subjects: 850
Study 21492636 — intervention group
Group type: COMPARATOR
Intervention: ICP/CPP management only (Group A)
Number of subjects: 45
Study 21492636 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP/CPP guided with mild hypothermia (Group B)
Number of subjects: 45
Study 21492636 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mild hypothermia and P(ti)o(2) guided with CPP management (Group C)
Number of subjects: 45
Study 18555911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated multidisciplinary, family-based preventive cardiology programme (INT)
Number of subjects: 1589
Study 16229368 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 16229368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0
Study 16229368 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment method
Number of subjects: 0
Study 12201326 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg ethinylestradiol (EE) + 100 μg levonorgestrel (LNG)
Number of subjects: 18
Study 10030555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin 0.1% solution
Number of subjects: 50
Study 10030555 — intervention group
Group type: COMPARATOR
Intervention: Topical dexamethasone phosphate 0.1% solution
Number of subjects: 50
Study 7573865 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% halothane
Number of subjects: 60
Study 7573865 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% halothane
Number of subjects: 60
Study 7573865 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% enflurane
Number of subjects: 60
Study 7573865 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% halothane (longer duration)
Number of subjects: 60
Study 2037853 — intervention group
Group type: EXPERIMENTAL
Intervention: Active negative pressure ventilation
Number of subjects: 184
Study 2037853 — intervention group
Group type: COMPARATOR
Intervention: Sham negative pressure ventilation
Number of subjects: 184
Study 7010995 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin (0.1 IU/kg in three doses per week)
Number of subjects: 12
Study 7010995 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin (0.1 IU/kg in three doses per week) + Oxandrolone (0.1 mg/kg/day)
Number of subjects: 12
Study 7010995 — intervention group
Group type: COMPARATOR
Intervention: Control (Somatropin alone)
Number of subjects: 12
Study 31435774 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg three times daily initially (900 mg), with 300 mg weekly incremental dose till pain was controlled, maximum daily dose of 2700 mg
Number of subjects: 60
Study 31435774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28323503 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO 25 mg QD
Number of subjects: 30
Study 28323503 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO 25 mg QD and PIO 30 mg QD
Number of subjects: 30
Study 28323503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ALO and ALO-PI
Number of subjects: 30
Study 25743855 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant + Dexamethasone (A + D)
Number of subjects: 303
Study 25743855 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide + Dexamethasone (M + D)
Number of subjects: 303
Study 23472765 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic enteral feedings (15 mL/kg/d) during indomethacin or ibuprofen treatment (n = 81)
Number of subjects: 177
Study 23472765 — intervention group
Group type: COMPARATOR
Intervention: No feeds (fasting [nil per os] group) during indomethacin or ibuprofen treatment (n = 96)
Number of subjects: 177
Study 21214369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (LILT) using a 630 nm diode laser
Number of subjects: 30
Study 21214369 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (Dexamethason mouth wash)
Number of subjects: 30
Study 19391533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecking moxibustion therapy
Number of subjects: 50
Study 19391533 — intervention group
Group type: COMPARATOR
Intervention: Common acupuncture
Number of subjects: 50
Study 17051872 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ionic toothbrush (equipped with lithium battery)
Number of subjects: 20
Study 17051872 — intervention group
Group type: COMPARATOR
Intervention: Inactive ionic toothbrush (without lithium battery)
Number of subjects: 20
Study 12772004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 221